Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHIRISH MADHAV GADGEEL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1033156534
CMS profile
273900
Location
DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$58,003.31

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHIRISH MADHAV GADGEEL

NPI 1033156534 · CMS profile ID 273900

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DETROIT, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHIRISH MADHAV GADGEEL, NPI 1033156534, CMS profile ID 273900, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1033156534?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $58,003.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $142.6203/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078742908 CMS
Janssen Biotech, Inc. $826.3502/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078743148 CMS
PFIZER INC. $133.6802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131587587 CMS
AstraZeneca Pharmaceuticals LP $52.3902/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533846 CMS
AstraZeneca Pharmaceuticals LP $22.1702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110542191 CMS
AstraZeneca Pharmaceuticals LP $49.2502/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110549756 CMS
AstraZeneca Pharmaceuticals LP $80.1802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552422 CMS
AstraZeneca Pharmaceuticals LP $45.2602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110553492 CMS
F. Hoffmann-La Roche AG $570.0001/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133112887 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $89,929.97 91
PY2020 $66,981.90 49
PY2021 $44,559.66 29
PY2022 $27,957.34 33
PY2023 $47,524.45 46
PY2024 $58,003.31 59
PY2025 $77,559.08 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,147.14 8
PY2025 Principal investigator $1,651,253.73 148
PY2024 Recipient $14,634.25 13
PY2024 Principal investigator $1,727,359.50 245
PY2023 Recipient $2,730.10 5
PY2023 Principal investigator $1,514,832.69 236
PY2022 Recipient $477.67 2
PY2022 Principal investigator $2,007,709.06 253
PY2021 Recipient $9,503.99 8
PY2021 Principal investigator $1,945,999.89 175
PY2020 Recipient $20,324.87 20
PY2020 Principal investigator $593,845.08 78
PY2019 Principal investigator $1,160,035.39 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

156 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202412425
Principal investigator 1 Merck Sharp & Dohme LLC $1,116.11 12/31/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer NSCLC KEYNOTE-799. No dispute reported 06/30/2026 1232927359
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 12/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350713
Principal investigator 1 Daiichi Sankyo Inc. $4,550.00 12/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350715
Principal investigator 1 Daiichi Sankyo Inc. $500.00 12/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350717
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350719
Principal investigator 1 Genentech, Inc. $4,598.00 12/03/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211544899
Recipient ABBVIE INC. $725.00 12/01/2025 Covered Recipient Physician Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202398235
Principal investigator 1 Janssen Research & Development, LLC $7,230.00 12/01/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361152
Principal investigator 1 PFIZER INC. $29,290.30 11/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228728209
Principal investigator 1 Daiichi Sankyo Inc. $4,799.00 11/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U102 No dispute reported 06/30/2026 1223350743
Principal investigator 1 Daiichi Sankyo Inc. $450.00 11/17/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350685
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 11/17/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350687
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 11/17/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350689
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 11/17/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350691
Principal investigator 1 PFIZER INC. $21,054.80 11/04/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228730709
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 10/31/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U102 No dispute reported 06/30/2026 1223350741
Principal investigator 1 ABBVIE INC. $4,550.00 10/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412347
Principal investigator 1 ABBVIE INC. $3,500.00 10/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412352
Principal investigator 1 ABBVIE INC. $500.00 10/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412356
Principal investigator 1 ABBVIE INC. $2,500.00 10/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412360
Recipient F. Hoffmann-La Roche AG $2.01 10/29/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211538913
Recipient F. Hoffmann-La Roche AG $0.53 10/23/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211538916
Recipient F. Hoffmann-La Roche AG $0.47 10/23/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211538919
Principal investigator 1 Daiichi Sankyo Inc. $1,206.60 10/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350761
Principal investigator 1 Daiichi Sankyo Inc. $11,050.00 10/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350763
Principal investigator 1 Genmab U.S., Inc. $186.25 10/14/2025 Non-covered Recipient Entity
HENRY FORD HEALTH SYSTEM
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235930610
Principal investigator 1 Genmab U.S., Inc. $77,457.50 10/14/2025 Non-covered Recipient Entity
HENRY FORD HEALTH SYSTEM
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235930613
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 10/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U201 No dispute reported 06/30/2026 1223350747
Principal investigator 1 Daiichi Sankyo Inc. $6,507.00 10/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U201 No dispute reported 06/30/2026 1223350749
Principal investigator 1 ABBVIE INC. $1,404.00 09/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412330
Principal investigator 1 ABBVIE INC. $780.00 09/19/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412308
Principal investigator 1 ABBVIE INC. $1,500.00 09/19/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412312
Principal investigator 1 ABBVIE INC. $1,000.00 09/19/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412316
Principal investigator 1 Genentech, Inc. $5,868.30 09/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211545044
Principal investigator 1 Genentech, Inc. $11,489.40 09/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211545049
Principal investigator 1 Genentech, Inc. $1,311.00 09/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211545052
Principal investigator 1 Genentech, Inc. $1,750.00 09/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211545056
Principal investigator 1 Genentech, Inc. $780.00 09/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211545059
Principal investigator 1 Daiichi Sankyo Inc. $21,800.00 09/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350711
Principal investigator 1 Genmab U.S., Inc. $116.00 08/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235923783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.60 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,154.00 08/21/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128540
Principal investigator 1 Daiichi Sankyo Inc. $7,013.52 08/19/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350759
Principal investigator 1 Genentech, Inc. $4,598.00 08/19/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211544868
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 08/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350683
Principal investigator 1 PFIZER INC. $7,600.00 08/14/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228788935
Principal investigator 1 Daiichi Sankyo Inc. $93,558.81 08/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350757
Principal investigator 1 ABBVIE INC. $3,250.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412223
Principal investigator 1 ABBVIE INC. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412228
Principal investigator 1 ABBVIE INC. $6,000.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412232
Principal investigator 1 ABBVIE INC. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412236
Principal investigator 1 ABBVIE INC. $3,000.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412242
Principal investigator 1 ABBVIE INC. $21,800.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412247
Principal investigator 1 ABBVIE INC. $500.00 08/01/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412249
Principal investigator 1 Genmab U.S., Inc. $5,968.00 07/25/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235923779
Principal investigator 1 Eli Lilly and Company $43,170.00 07/17/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187877673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,090.00 07/17/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128510
Principal investigator 1 Janssen Research & Development, LLC $4,510.00 07/10/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,148.75 07/10/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128508
Principal investigator 1 Janssen Research & Development, LLC $2,586.00 07/07/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361288
Principal investigator 1 AstraZeneca Pharmaceuticals LP $170,317.97 06/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185548241
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,197.00 06/25/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
101623 No dispute reported 06/30/2026 1252496753
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,500.00 06/25/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
101623 No dispute reported 06/30/2026 1252496755
Principal investigator 1 Genmab U.S., Inc. $7,000.00 06/24/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235923753
Principal investigator 1 Mirati Therapeutics, Inc. $4,358.07 06/19/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 No dispute reported 06/30/2026 1236530079
Principal investigator 1 Genentech, Inc. $9,580.20 06/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1211544673
Principal investigator 1 Genentech, Inc. $20,356.75 06/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545012
Principal investigator 1 Genentech, Inc. $32,129.80 06/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545016
Principal investigator 1 Genentech, Inc. $1,024.90 06/12/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.75 06/12/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128502
Principal investigator 1 Daiichi Sankyo Inc. $978.00 05/28/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350755
Principal investigator 1 Genentech, Inc. $1,000.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211544990
Principal investigator 1 Genentech, Inc. $700.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211544995
Principal investigator 1 Genentech, Inc. $1,412.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211544999
Principal investigator 1 Genentech, Inc. $2,400.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545004
Principal investigator 1 Genentech, Inc. $674.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545021
Principal investigator 1 Genentech, Inc. $9,224.10 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545032
Principal investigator 1 Genentech, Inc. $7,991.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545036
Principal investigator 1 Genentech, Inc. $750.00 05/27/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
Ph I Ib II of TIGIT aPDL 1 No dispute reported 06/30/2026 1211545040
Principal investigator 1 Daiichi Sankyo Inc. $8,142.24 05/22/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350753
Principal investigator 1 Incyte Corporation $6,138.70 05/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475209
Principal investigator 1 Genentech, Inc. $39,050.00 05/13/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211544830
Principal investigator 1 Genentech, Inc. $39,050.00 05/13/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211544834
Principal investigator 1 ABBVIE INC. $3,688.00 04/28/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412165
Principal investigator 1 Amgen Inc. $20,643.68 04/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246637730
Principal investigator 1 Daiichi Sankyo Inc. $2,394.90 04/23/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350681
Principal investigator 1 Daiichi Sankyo Inc. $327.60 04/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U102 No dispute reported 06/30/2026 1223350737
Principal investigator 1 Daiichi Sankyo Inc. $6,309.00 04/18/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U102 No dispute reported 06/30/2026 1223350739
Principal investigator 1 PFIZER INC. $5,000.00 04/16/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228780256
Principal investigator 1 Mirati Therapeutics, Inc. $18,330.74 04/15/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio No dispute reported 06/30/2026 1236530071
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350701
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350703
Principal investigator 1 Daiichi Sankyo Inc. $400.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350705
Principal investigator 1 Daiichi Sankyo Inc. $5,000.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350707
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 04/09/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-189 No dispute reported 06/30/2026 1223350709
Principal investigator 1 Amgen Inc. $21,513.63 04/08/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300) No dispute reported 06/30/2026 1246637728
Principal investigator 1 Genentech, Inc. $5,754.00 04/07/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211544687
Principal investigator 1 Janssen Research & Development, LLC $2,725.00 04/07/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361411
Principal investigator 1 Genmab U.S., Inc. $7,428.22 04/04/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1235923749
Principal investigator 1 Genentech, Inc. $29,796.00 04/01/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 No dispute reported 06/30/2026 1211544843
Recipient F. Hoffmann-La Roche AG $300.83 03/31/2025 Covered Recipient Physician B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211538905
Recipient F. Hoffmann-La Roche AG $3,402.92 03/31/2025 Covered Recipient Physician Real-world Characteristics and Survival Outcomes of Patients with Metastatic ALK Fusion-positive Solid Tumors Treated with Standard-of-care Therapies No dispute reported 06/30/2026 1211538909
Recipient F. Hoffmann-La Roche AG $380.74 03/31/2025 Covered Recipient Physician RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 No dispute reported 06/30/2026 1211538923
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,250.00 03/28/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185548245
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 03/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U201 No dispute reported 06/30/2026 1223350745
Principal investigator 1 ABBVIE INC. $2,063.00 03/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412125
Principal investigator 1 ABBVIE INC. $4,784.00 03/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412129
Principal investigator 1 ABBVIE INC. $2,267.00 03/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412133
Principal investigator 1 ABBVIE INC. $5,784.00 03/26/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412137
Principal investigator 1 Daiichi Sankyo Inc. $450.00 03/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350693
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350695
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 03/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350697
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 03/14/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS7300-127 No dispute reported 06/30/2026 1223350699
Principal investigator 1 ABBVIE INC. $2,514.00 03/12/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412113
Principal investigator 1 ABBVIE INC. $2,267.00 03/12/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412117
Principal investigator 1 ABBVIE INC. $4,784.00 03/12/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412121
Principal investigator 1 PFIZER INC. $1,344.00 03/12/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228784038
Principal investigator 1 ABBVIE INC. $36,050.00 03/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202412099
Principal investigator 1 ABBVIE INC. $2,267.00 03/03/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412088
Principal investigator 1 ABBVIE INC. $2,267.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412052
Principal investigator 1 ABBVIE INC. $3,072.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412055
Principal investigator 1 ABBVIE INC. $2,825.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412059
Principal investigator 1 ABBVIE INC. $2,514.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412063
Principal investigator 1 ABBVIE INC. $5,099.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412067
Principal investigator 1 ABBVIE INC. $2,063.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412072
Principal investigator 1 ABBVIE INC. $2,764.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412077
Principal investigator 1 ABBVIE INC. $2,063.00 02/27/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202412080
Principal investigator 1 Incyte Corporation $1,000.00 02/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475189
Principal investigator 1 Incyte Corporation $800.00 02/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475197
Principal investigator 1 Incyte Corporation $1,200.00 02/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475201
Principal investigator 1 Incyte Corporation $750.00 02/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475205
Principal investigator 1 Daiichi Sankyo Inc. $24,199.81 02/20/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
U31402-A-U103 No dispute reported 06/30/2026 1223350751
Principal investigator 1 Janssen Research & Development, LLC $50,073.00 02/13/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361344
Principal investigator 1 Genentech, Inc. $2,300.00 02/12/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1211544678
Principal investigator 1 Janssen Research & Development, LLC $3,084.00 02/06/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361298
Principal investigator 1 Janssen Research & Development, LLC $3,941.00 02/06/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175361309
Principal investigator 1 PFIZER INC. $4,524.00 02/05/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228770618
Recipient Amgen Inc. $2,334.64 02/01/2025 Covered Recipient Physician Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer No dispute reported 06/30/2026 1246636816
Principal investigator 1 Daiichi Sankyo Inc. $2,067.00 01/30/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
DS1062-A-U202 No dispute reported 06/30/2026 1223350661
Principal investigator 1 ABBVIE INC. $2,764.00 01/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202412014
Principal investigator 1 ABBVIE INC. $5,360.00 01/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202412018
Principal investigator 1 ABBVIE INC. $4,731.00 01/29/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202412022
Principal investigator 1 F. Hoffmann-La Roche AG $8,004.00 01/29/2025 Covered Recipient Teaching Hospital
Henry Ford West Bloomfield Hospital
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211544952
Principal investigator 1 Incyte Corporation $2,500.00 01/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors No dispute reported 06/30/2026 1240475192
Principal investigator 1 Genentech, Inc. $2,211.00 01/21/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211544683
Principal investigator 1 AstraZeneca UK Limited $135,075.03 01/17/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced solid tumors No dispute reported 06/30/2026 1185548243
Principal investigator 1 Mirati Therapeutics, Inc. $27,080.20 01/15/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,900.00 01/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 01/07/2025 Covered Recipient Teaching Hospital
HENRY FORD HOSPITAL
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184128464
Principal investigator 1 Amgen Inc. $292,522.50 01/02/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) No dispute reported 06/30/2026 1246637734